SEARCH

SEARCH BY CITATION

References

  • 1
    Wright PF, Webster RG. Orthomyxoviruses. In: KnipeDM, HowleyPM, GriffinDE, LambRA, MartinMA, RoizmanB, StrausSE, eds. Fields Virology, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001,153379[Chapter 47].
  • 2
    Webster RG, Bean WJ. Evolution and ecology of influenza viruses: interspecies transmission. In: NicholsonKG, WebsterKG, HayA, eds. Textbook of Influenza. Oxford, UK: Blackwell Science, 1998, 10919.
  • 3
    Taubenberger JK, Reid AH, Krafft AE, Bijwaard KE, Fanning TG. Initial genetic characterization of the 1918 ‘Spanish’ influenza virus. Science 1997;21: 17936.
  • 4
    Yasuda J, Shortridge KF, Shimizu Y, Kida H. Related molecular evidence for a role of domestic ducks in the introduction of avian H3 influenza viruses to pigs in southern China, where the A/Hong Kong/68 (H3N2) strain emerged. J Gen Virol 1991;72: 200710.
  • 5
    Scholtissek C, Hinshaw VS, Olsen CW. Influenza in pigs and their role as intermediate host. In: NicholsonKG, WebsterKG, HayA, eds. Textbook of Influenza. Oxford, UK: Blackwell Science, 1998, 13745.
  • 6
    Lui K-J, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987;77: 7126.
  • 7
    Simonsen L, Schonberger LB, Stroup DF, Arden NH, Cox NJ. Impact of influenza on mortality in the USA. In: BrownLE, HampsonAW, WebsterRG, eds. Options for the Control of Influenza III. New York, NY: Elsevier Science, 1996, 2633.
  • 8
    Brammer TL, Murray EL, Fukuda K, Hall HE, Klimov A, Cox NJ. Surveillance for influenza in the United States, 1997–98, 1998–99, and 1999–00 seasons. MMWR CDC Surveill Summ 2002;51: 110.
  • 9
    Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999;5: 65971.
  • 10
    Blitz SG. Developments in the care of influenza patients: priorities and perspectives. JCOM 2000;7: 6374.
  • 11
    Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2003;52: 134[No. RR-8].
  • 12
    WHO. Manual on animal influenza diagnosis and surveillance (WHO/CDS/CSR/NCS/2002.5) (available from: http://www.who.int/).
  • 13
    Centers for Disease Control and Prevention. Guideline for infection control in healthcare personnel, 1998. Infect Control Hosp Epidemiol 1998;19: 41059.
  • 14
    Couch RB. Advances in influenza virus vaccine research. Ann N Y Acad Sci 1993;685: 80312.
  • 15
    Beyer WE, Palache AM, De Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002;20: 134053.
  • 16
    Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infection in infants. Pediatr Infect Dis J 1997;16: 10658.
  • 17
    Chiu SS, Lau TL, Chan KH, Wong WHS, Peiris JSM. Influenza related hospitalizations among children in Hong Kong. N Engl J Med 2002;347: 2097103.
  • 18
    Powers DC, Smith GE, Anderson EL et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis 1995;171: 15959.
  • 19
    Van Essen GA, Palache AM, Forleo E, Fedson DS. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly countries. Vaccine 2003;21: 17805.
  • 20
    Murphy BR, Chalhub EG, Nusinoff SR, Kasel J, Chanock RM. Temperature-sensitive mutants of influenza virus. III. Further characterization of the ts-[E] influenza A recombinant (H3N2) virus in man. J Infect Dis 1973;128: 47987.
  • 21
    Clements ML, O'Donnell S, Levine MM, Chanock RM, Murphy BR. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun 1983;40: 104451.
  • 22
    Clements ML, Betts RF, Tierney El, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986;24: 15760.
  • 23
    Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza. A virus vaccine. J Clin Microbiol 1986;23: 6672.
  • 24
    Potter CW. Chronicle of influenza pandemics. In: NicholsonKG, WebsterKG, HayA, eds. Textbook of Influenza. Oxford, UK: Blackwell Science, 1998, 318.
  • 25
    Noble GR. Epidemiological and clinical aspects of influenza. In: BeareAS, ed. Basic and Applied Influenza Research. Boca Raton, FL: CRC Press, 1982, 1179.
  • 26
    Cretescu L, Beare AS, Schild GC. Formation of antibody to matrix protein in experimental human influenza A virus infections. Infect Immun 1978;22: 3227.
  • 27
    Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med J 1979;35: 6975.
  • 28
    Askonas BA, McMichael AJ, Webster RG. The immune response to influenza viruses and the problem of protection against infection. In: BeareAS, ed. Basic and Applied Influenza Research. Boca Raton, FL: CRC Press, 1982, 15988.
  • 29
    Artenstein MS, Bellanti JA, Buescher EL. Identification of the antiviral substances in nasal secretions. Proc Soc Exp Biol Med 1964;117: 55864.
  • 30
    Mazanec MB, Coudret CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 1995;69: 133944.
  • 31
    Rossen RD, Butler WT, Waldman RH et al. The proteins in nasal secretion. II. A longitudinal study of IgA and neutralizing antibody levels in nasal washings from men infected with influenza virus. JAMA 1970;211: 115761.
  • 32
    Murphy BR, Clements ML. The systemic and mucosal immune response of humans to influenza A virus. In: MesteckyJ, McGheeJR, eds. Current Topics in Microbiology and Immunology. New York, NY: Springer Verlag, 1989, 10716.
  • 33
    Wright PF, Murphy BR, Kervina M, Lawrence EM, Phelan MA, Karzon DT. Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect Immun 1983;40: 10925.
  • 34
    Brokstad KA, Cox RJ, Eriksson JC, Olofsson J, Jonsson R, Davidsson A. High prevalence of influenza specific antibody secreting cells in nasal mucosa. Scand J Immunol 2001;54: 2437.
  • 35
    Cox NJ, Subbarao K. Influenza. Lancet 1999;354: 127782.
  • 36
    Cox RJ, Brokstad KA, Zuckerman MA, Wood JM, Haaheim LR, Oxford JS. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 1994;12: 9939.
  • 37
    Callard RE. Specific in vitro antibody response to influenza virus by human blood lymphocytes. Nature (London) 1979;282: 7346.
  • 38
    Yarchoan R, Murphy BR, Strober W, Schneider HS, Nelson DL. Specific anti-influenza virus antibody production in vitro by human peripheral blood mononuclear cells. J Immunol 1981;127: 255894.
  • 39
    Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983;37: 52949.
  • 40
    Brown TA, Murphy BR, Radl J, Haaijman JJ, Mestecky J. Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J Clin Microbiol 1985;22: 25964.
  • 41
    Jurgensen PF, Olsen GN, Johnson JE III et al. Immune response of the human respiratory tract. II. Cell-mediated immunity in the lower respiratory tract to tuberculin and mumps and influenza viruses. J Infect Dis 1973;128: 7305.
  • 42
    Yewdell JW, Hackett CJ. The specificity and function of T lymphocytes induced by influenza A viruses. In: KrugR, ed. The Influenza Viruses. New York, NY: Plenum Press, 1989.
  • 43
    Quinnan GV, Ennis FA, Tuazon CU et al. Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine. Infect Immun 1980;30: 3629.
  • 44
    Ruben FL, Bachmayer H, Fireman P. Parameters of humoral and cellular immunity to influenza A/USSR/90/77(H1N1): virus in various age groups. J Infect Dis 1980;142: 699703.
  • 45
    McMichael AJ, Gotch FM, Noble GR, Beare PAS. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983;309: 137.
  • 46
    McMichael AJ, Michie CA, Gotch FM, Smith GL, Moss B. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 1986;67: 71926.
  • 47
    Ennis FA, Rook AH, Yi-Hua QY et al. HLA-restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet 1981;2: 88791.
  • 48
    Fleischer B, Becht H, Rott R. Recognition of viral antigens by human influenza A virus-specific T lymphocyte clones. J Immunol 1985;135: 28004.
  • 49
    Ennis FA, Yi-Hua Q, Schild GC. Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines. J Gen Virol 1982;58: 27381.
  • 50
    Doherty PC, Riberdy JM, Christensen JP. Memory and recall CD8+ T cell responses to the influenza A viruses. In: OsterhausA, CoxNJ, HampsonAW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 293300.
  • 51
    Gerhard W, Mozdanowska K. Roles of CD4+ T and B cells in influenza virus infection. In: OsterhausA, CoxNJ, HampsonAW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 3118.
  • 52
    Nguyen HH, Van Ginkel FW, Vu HL, McGhee JR, Mestecky J. Mechanism of heterosubtypic immunity to influenza A virus infection. In: OsterhausA, CoxNJ, HampsonAW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 33340.
  • 53
    Kilbourne ED, Couch RB, Kasel JA et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995;13: 1799803.
  • 54
    Glück R, Wegmann A. Liposomal presentation of influenza antigens. In: NicholsonKG, WebsterRG, HayAJ, eds. Textbook of Influenza. Oxford, UK: Blackwell Science, 1998, 37390.
  • 55
    Crovari P, Garbino E, Bruzzone B, Herzog C, Glück R. Intranasal influenza vaccine: protective efficacy in children and adults. In: OsterhausA, CoxNJ, HampsonAW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 9658.
  • 56
    Glück R. Preclinical and clinical evaluation of a new virosomal intranasal influenza vaccine. In: OsterhausA, CoxNJ, HampsonAW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 96978.
  • 57
    Plante M, Joned D, Allard F et al. Nasal proteosome subunit flu vaccine elicits mucosal IgA, serum HAI and protection comparable to conventional injectable flu vaccine. In: OsterhausA, CoxNJ, HampsonAW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 97984.
  • 58
    Webster RG. DNA vaccination: a potential future strategy. In: NicholsonKG, WebsterRG, HayAJ, eds. Textbook of Influenza. Oxford, UK: Blackwell Science, 1998, 41021.
  • 59
    Ignuzzi M, Gerbaud S, Van Der Werf S, Escriou N. Replicons from positive strand RNA viruses for naked RNA immunization against influenza. In: OsterhausA, CoxNJ, HampsonAW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 9239.
  • 60
    Ott G, Barchfel GL, Van Nest G. Enhancement of humoral response against human influenza vaccine with simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995;3: 155762.
  • 61
    Wyde PR, Guzman E, Gilbert BE, Couch RB. Immunogenicity and protection in mice given inactivated influenza vaccine, MPL, QS-21 or QS-7. In: OsterhausA, CoxNJ, HampsonAW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 9991005.
  • 62
    Tumpey TM, Clements JD, Katz JM. Mucosal vaccination protects mice against influenza A heterosubtypic challenge. In: OsterhausA, CoxNJ, HampsonAW, eds. Options for the Control of Influenza IV. New York, NY: Elsevier Science, 2001, 98592.
  • 63
    Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Friedman G. Deydroepiandroesterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Vaccine 1995;13: 14458.
  • 64
    Ahmed FA, Singleton JA, Franks AL. Influenza vaccination for healthy adults. N Engl J Med 2001;345: 15437.
  • 65
    Nichol KL. Efficacy/clinical effectiveness of inactivated influenza vaccines in adults. In: NicholsonKG, WebsterRG, HayAJ, eds. Textbook of Influenza. Oxford, UK: Blackwell Science, 1998a, 35872.
  • 66
    Gross PA, Hermongenes AW, Sacks HS, Lau J, Levandowski RA. Efficacy of influenza vaccines in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995;123: 51827.
  • 67
    Nichol KL, Wuorenms J, Von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998b;158: 176976.
  • 68
    Zuckerman M, Cox R, Taylor J, Wood J, Haaheim L, Oxford J. Rapid immune response to influenza vaccination. Lancet 1993;342: 1113.
  • 69
    Oxford JS, Schild GC, Potter CW, Jennings R. Specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccine and by natural infection. J Hyg 1979;82: 5161.
  • 70
    La Montague JR, Noble GR, Quinnan GV et al. Summary of clinical trials of inactivated influenza vaccines – 1978. Rev Infect Dis 1983;5: 72336.
  • 71
    Daubeney P, Taylor CJ, McGaw J et al. Immunogenicity and tolerability of a trivalent influenza subunit vaccine (Influvac) in high-risk children aged 6 months to 4 years. Br J Clin Pract 1997;51: 8790.
  • 72
    Gonzalez M, Pirez MC, Wars E, Dibarbourne J, Garcia A, Picolet H. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. Arch Dis Child 2000;83: 48891.
  • 73
    Brokstad KA, Cox RJ, Olofsson J, Jonsson R, Haaheim LR. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 1995;171: 198203.
  • 74
    Brokstad KA, Cox RJ, Major D, Wood JM, Haaheim LR. Cross-reaction but no avidity change of the serum antibody response after influenza vaccination. Vaccine 1995;13: 15228.
  • 75
    El-Madhun AS, Cox RJ, Soreide A, Olofsson J, Haaheim LR. Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J Infect Dis 1998;178: 9339.
  • 76
    El-Madhun AS, Cox RJ, Haaheim LR. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J Infect Dis 1999;180: 135660.
  • 77
    Cox RJ, Brokstad KA. The postvaccination antibody response to influenza virus proteins. APMIS 1999;107: 28996.
  • 78
    Brokstad KA, Cox RJ, Oxford JS, Haaheim LR. IgA, IgA subclasses, and secretory component levels in oral fluid collected from subjects after parental influenza vaccination. J Infect Dis 1995;171: 10724.
  • 79
    Brokstad KA, Eriksson JC, Cox RJ et al. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis 2002;185: 87884.
  • 80
    Eriksson JC, Davidsson A, Garberg H, Brokstad KA. Lymphocyte distribution in the tonsils prior to and after influenza vaccination. Vaccine 2003;22: 5763.
  • 81
    El-Madhun AS, Cox RJ, Seime A, Sovik O, Haaheim LR. Systemic and local immune responses after parenteral influenza vaccination in juvenile diabetic patients and healthy controls: results from a pilot study. Vaccine 1998;16: 15660.
  • 82
    Cox RJ, Mykkeltvedt E, Sjursen H, Haaheim LR. The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine 2001;19: 47439.
  • 83
    Ogra PL, Mestecky J, Lamm ME, Strober W, Bienstock J, McGhee JR, eds. Mucosal Immunology, 2nd edn. New York, NY: Academic Press, 1999.
  • 84
    Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001;14: 43045.
  • 85
    Abramson JS. Intranasal, cold-adapted, live, attenuated influenza vaccine. Pediatr Infect Dis J 1999;18: 11034.
  • 86
    King JC, Lagos R, Bernstein DI et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis 1998;177: 13947.
  • 87
    Mendelman PM, Cordova J, Cho I. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine 2001;19: 22216.
  • 88
    Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002;15: 295323.
  • 89
    Wareing MD, Tannock GA. Live attenuated vaccines against influenza: an historical review. Vaccine 2001;19: 33203.
  • 90
    Palese P, Garcia-Sastre A. Influenza vaccines: present and future. J Clin Invest 2002;110: 913.
  • 91
    Potter CW, Jennings R, Clark A, Ali M. Interference following dual inoculation with influenza A (H3N2) and (H1N1) viruses in ferrets and volunteers. J Med Virol 1983;11: 7786.
  • 92
    Keitel WA, Couch RB, Quarles JM, Cate TR, Baxter B, Maassab HF. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis 1993;167: 30511.
  • 93
    Keitel WA, Piedra PA. Live cold-adapted, reassortant influenza vaccines (USA). In: Nicholson, KG, WebsterRG, HayAJ, eds. Textbook of Influenza. Oxford, UK: Blackwell Science, 1998, 37390.
  • 94
    Swierkosz EM, Newman FK, Anderson EL, Nugent SL, Mills GB, Belshe RB. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children. J Infect Dis 1994;169: 11214.
  • 95
    Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998;338: 140512.
  • 96
    Longini IM, Halloran ME, Nizam A et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine 2000;17: 19029.
  • 97
    Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000a; 181: 11337.
  • 98
    Rudenko LG, Slepushkin AN, Monto AS et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 1993;168: 8817.
  • 99
    Treanor JJ, Mattison HR, Dumyati G et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992;117: 62533.
  • 100
    Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994;169: 6876.
  • 101
    Boyce TG, Poland GA. Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review. Biomed Pharmacother 2000;54: 108.
  • 102
    Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 2001;20: 73340.
  • 103
    Piedra PA, Yan L, Kotloff K et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 2002;110: 66272.
  • 104
    Johnson PR Jr, Feldman S, Thompson JM, Mahoney JD, Wright PF. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol 1985;17: 32535.
  • 105
    Boyce TG, Hsu HH, Sannella EC et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 2000;19: 21726.
  • 106
    Ada GL, Jones PD. The immune response to influenza infection. Curr Top Microbiol Immunol 1986;128: 154.
  • 107
    Gruber WC, Taber LH, Glezen WP et al. Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child 1990;144: 595600.
  • 108
    Gruber WC, Darden PM, Still JG, Lohr J, Reed G, Wright PF. Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose–response. Vaccine 1997;15: 137984.
  • 109
    Powers DC, Sears SD, Murphy BR et al. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol 1989;27: 266671.
  • 110
    Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (London) 1972;70: 76777.
  • 111
    Kendal AP, Pereira MS, Skehel JJ. Concepts and Procedures for Laboratory Based Influenza Surveillance. Washington DC: US Department of Health and Human Services, 1982.
  • 112
    Heilman C, La Montagne JR. Influenza: status and prospects for its prevention, therapy, and control. Pediatr Clin North Am 1990;37: 66988.
  • 113
    Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live, cod-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999;18: 899906.
  • 114
    Treanor JJ, Betts RF. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Vaccine 1998;16: 175660.
  • 115
    Jackson LA, Holmes SJ, Mendelman PM, Huggins L, Cho I, Rhorer J. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 1999;17: 19059.
  • 116
    Nichol KL. Live attenuated influenza virus vaccines: new options for the prevention of influenza. Vaccine 2001;19: 43737.
  • 117
    Stepanova L, Naykhin A, Kolmskog C et al. The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly. J Clin Virol 2002;24: 193201.
  • 118
    Clements ML, Betts RF, Murphy BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet 1984;1: 7058.
  • 119
    Monto AS, Davenport FM, Napier JA, Francis T Jr. Effect of vaccination of a school-age population upon the course of an A2-Hong Kong influenza epidemic. Bull World Health Organ 1969;41: 53742.
  • 120
    Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis 1970;122: 1625.
  • 121
    Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974–76. N Engl J Med 1978;298: 58792.
  • 122
    Munoz FM. The impact of influenza in children. Semin Pediatr Infect Dis 2002;13: 728.
  • 123
    Nichol KL, Mendelman PM, Mallon KP et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomised controlled trial. JAMA 1999;282: 13744.